We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
Read MoreHide Full Article
STERIS plc (STE - Free Report) has been gaining from robust segmental growth. Expansions in both margins, and the product and service portfolio along with increased fiscal 2020 guidance buoy optimism. However, downsides might result from customer consolidation. Also, the coronavirus pandemic is adversely impacting the stock price.
Over the past year, shares of the Zacks Rank #1 (Strong Buy) company have outperformed its industry. The company has gained 10.5% against a 15.9% decline of its industry. Also, it has outperformed the S&P 500’s 14.2% fall during the same period.
The renowned provider of infection prevention, and other procedural products and services has a market capitalization of $11.77 billion. The company projects 6.5% growth for the fourth quarter of fiscal 2020 and expects to maintain its strong segmental performance. Further, it delivered a positive earnings surprise of 5.8%, on average, in the trailing four quarters.
Let’s delve deeper.
Infection Prevention and Sterilization Wing Holds Potential: STERIS continues to benefit from the integration of the U.K.-based outsourced sterilization services provider, Synergy Health, as it paves the way for STERIS’ global leadership in infection prevention and sterilization. The consolidation boosted STERIS' presence in the international markets as it combines the company’s strong presence in North America with Synergy's solid footprint across Europe, the Asia Pacific and Latin America.
Potential of Healthcare and Pharmaceutical Industries Hold Prospect: We are upbeat about STERIS' growth potential in the healthcare and pharmaceutical industries. With life expectancy on the rise globally, a larger aging population increases the demand for medical procedures. This, in turn, translates into higher use of single-use medical devices and surgical kits processed by the company.
Q3 Results Impressive: STERIS’ year-over-year organic revenue growth at constant currency in the fiscal third quarter was impressive. Contributions from elevated consumer demand and a broader portfolio of products and services bode well for the company. Expansion of both margins during the quarter is also encouraging. In addition, increased fiscal 2020 guidance instills investors’ confidence in the stock.
However, despite the upsides, the company’s stock price may witness a downturn due to several customers’ consolidations, which resulted partly from healthcare cost-reduction measures. Further, the ongoing coronavirus pandemic is pulling down share prices as a whole and leading to an economic crisis.
Estimate Trend
STERIS is witnessing a positive estimate revision trend for 2020. Over the past 60 days, the Zacks Consensus Estimate for its earnings has moved 0.7% north to $5.62.
The Zacks Consensus Estimate for the company’s fourth-quarter 2020 revenues is pegged at $807.5 million, suggesting a 5.1% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Add STERIS (STE) Stock in Your Portfolio
STERIS plc (STE - Free Report) has been gaining from robust segmental growth. Expansions in both margins, and the product and service portfolio along with increased fiscal 2020 guidance buoy optimism. However, downsides might result from customer consolidation. Also, the coronavirus pandemic is adversely impacting the stock price.
Over the past year, shares of the Zacks Rank #1 (Strong Buy) company have outperformed its industry. The company has gained 10.5% against a 15.9% decline of its industry. Also, it has outperformed the S&P 500’s 14.2% fall during the same period.
The renowned provider of infection prevention, and other procedural products and services has a market capitalization of $11.77 billion. The company projects 6.5% growth for the fourth quarter of fiscal 2020 and expects to maintain its strong segmental performance. Further, it delivered a positive earnings surprise of 5.8%, on average, in the trailing four quarters.
Let’s delve deeper.
Infection Prevention and Sterilization Wing Holds Potential: STERIS continues to benefit from the integration of the U.K.-based outsourced sterilization services provider, Synergy Health, as it paves the way for STERIS’ global leadership in infection prevention and sterilization. The consolidation boosted STERIS' presence in the international markets as it combines the company’s strong presence in North America with Synergy's solid footprint across Europe, the Asia Pacific and Latin America.
Potential of Healthcare and Pharmaceutical Industries Hold Prospect: We are upbeat about STERIS' growth potential in the healthcare and pharmaceutical industries. With life expectancy on the rise globally, a larger aging population increases the demand for medical procedures. This, in turn, translates into higher use of single-use medical devices and surgical kits processed by the company.
Q3 Results Impressive: STERIS’ year-over-year organic revenue growth at constant currency in the fiscal third quarter was impressive. Contributions from elevated consumer demand and a broader portfolio of products and services bode well for the company. Expansion of both margins during the quarter is also encouraging. In addition, increased fiscal 2020 guidance instills investors’ confidence in the stock.
However, despite the upsides, the company’s stock price may witness a downturn due to several customers’ consolidations, which resulted partly from healthcare cost-reduction measures. Further, the ongoing coronavirus pandemic is pulling down share prices as a whole and leading to an economic crisis.
Estimate Trend
STERIS is witnessing a positive estimate revision trend for 2020. Over the past 60 days, the Zacks Consensus Estimate for its earnings has moved 0.7% north to $5.62.
The Zacks Consensus Estimate for the company’s fourth-quarter 2020 revenues is pegged at $807.5 million, suggesting a 5.1% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>